Introduction
Previous work from our laboratories has shown that vascular endothelial cells functionally express a local autocrine-paracrine regulatory pathway driven by endogenously expressed, chemically authentic morphine, its cognate opiate alkaloidselective mu3 and mu4 receptors, and constitutive nitric oxide (NO). 1, 2 Morphine-mediated activation of NO/cyclic guanosine monophosphate signaling pathways results in significant vasodilatation, thereby establishing mu3 and mu4 opiate receptors as important potential therapeutic targets for restoring normotensive vascular tone in hypertensive syndromes. [1] [2] [3] Therefore, it is likely that mu3 and mu4 opiate receptors coupled to constitutive NO expression is tonically activated by low levels of endogenously expressed, chemically authentic morphine. 3 The presence of chemically authentic morphine has been shown in vascular endothelial cells obtained from human atria, 4 human white blood cells (WBCs), which also express mu3 and mu4 opiate receptors, 1, 5 human plasma 3, 6, 7 and several human cancer cell lines. 1, 2, 5, 8 Provocatively, we have also characterized a functionally competent mu3/ mu4 receptor/NO-coupled regulatory pathway in human multilineage progenitor cells (MLPCs), 9 thereby suggesting a fundamental role of morphine/NO-coupled developmental processes. 9 Recently, similar analyses have shown programmed expression of opioid peptide and opioid receptor genes in cultured neural progenitor cells at various stages of differentiation. 9 Human MLPCs derived from post-partum umbilical cord blood have recently been established as a high-resolution model for studying biochemical and molecular mechanisms underlying differentiation of multipotent progenitor cells into clonal cell lines (for example, adipocytes, osteoblasts, myocytes, vascular endothelial cells, neurons, astrocytes and oligodendrocytes). 9 As MLPCs are non-transformed, and non-immortalized, their potential for both proliferation and differentiation into phenotypically distinct clonal lines is temporally defined by the complex chemical profile of their respective microenvironments. Previous studies of opioid regulation of hematopoesis in adult animals from other groups have provided initial insights into the potential role of opioid processes in MLPC maturation. 9 In light of this recent work just noted, it is our contention that endogenous morphine is responsible for activating a mu3/mu4 receptor/NO-coupled regulatory pathway that drives basic cellular autocrine or paracrine processes. Accordingly, one of the key physiological roles of this pathway seems to be the homeostatic maintenance of normal vascular tone, which can only be achieved by close coupling of the vascular endothelium with circulating leukocytes. Endogenous morphine derived from defined cellular sources and circulating in plasma seems to provide an important caretaker role in promoting coordinated, on demand, vasomotor responsiveness, to diverse physiological stimuli. On the basis of these stated criteria, we sought to examine morphine-mediated changes in the expression of genes associated with hypertension using two independent cell models: preparations of human WBC and human MLPC.
Materials and methods

Human WBCs
Human blood was obtained from the Long Island Blood Services not individual donors (Melville, NY, USA). Human heparinized whole blood was immediately separated using 1-step polymorphs (Accurate Chemical and Scientific Corporation, Westbury, NY, USA) gradient medium. In all, 5 ml of heparinized blood was layered over 5 ml of polymorphs in a 14 ml roundbottom tube and then centrifuged for 35 min at 500 Â g in a swinging-bucket rotor at 18 1C. After centrifugation, the lower band consisting of polymorphonuclear cells was harvested in 14 ml tubes and then washed with 10 ml phosphate-buffered saline (Invitrogen, Carlsbad, CA, USA) by centrifugation for 10 min at 400 Â g. In addition, residual red blood cells were lysed using ACK (aluminium chloride potassium) lysing buffer (Current Protocols in Immunology, John Wiley & Sons, New York, NY, USA). Cells were exposed to 1 mM morphine for 2 h. This procedure was replicated three times and subjected to statistical analysis.
Stem cells: MLPC preparations
Frozen MLPC preparations were obtained from BioE, Inc., St Paul, MN, USA, quickly thawed in a 37 1C water bath and transferred to 75 cm 2 tissue culture flasks containing 15 ml of Mesenchymal Stem Cell Growth Medium Bullet Kit (Lonza, Walkersville, MD, USA; PT-3001). MLPCs were incubated overnight in a 5% CO 2 incubator at 37 1C followed by a change of medium. At 40% confluency, cells were detached using 15 ml of phosphate-buffered saline containing 0.1% ethylene glycol tetraacetic acid, pH 7.3. Detached MLPCs were pelleted by centrifugation (500 Â g for 7 min), re-seeded or used for pharmacological experiments and/or RNA extraction.
MLPCs derived from post-partum human umbilical cord blood (BioE, Inc.), are normal multi-potent progenitor cells that express genes found in progenitor stem cells (commercial source, see Cadet et al. 9 ). The MLPCs have been differentiated into different types of cells (adipocytes, osteoblasts, astrocytes, oligodendrocytes, myocytes, endothelial, neurons and hepato/pancreatic precursors), forming the endoderm, mesoderm and ectoderm of a developing embryo, and are capable of undergoing extensive differentiation. As MPLCs are normal, non-transformed and non-immortalized, they experience a reduced growth, and lose their proliferative and differentiating capacity after many passages. Thus, they can be grown in culture only to a maximum confluency of 40%.
Differentiation of MLPC into neural progenitor cells was accomplished in neural progenitor maintenance media containing human recombinant basic fibroblast growth factor, human recombinant epidermal growth factor, neural survival factor-1 (Lonza, CC-3209) supplemented with fibroblast growth factor-4 (Sigma-Aldrich Corp., St Louis, MO, USA), Glutamax I supplement (Invitrogen Life Technologies, Carlsbad, CA, USA) and penicillin and streptomycin (Invitrogen Life Technologies). After the development of neurospheres (10 days), the neurospheres were further differentiated into neurons by supplementing the neural progenitor maintenance media with 10 ng ml -1 brain-derived neurotrophic factor (Sigma-Aldrich) and 10 ng ml -1 neurotrophin-3 (Sigma-Aldrich) for 21 days. Medium was changed every 3-4 days. The differentiation media for the treated cells was exposed to morphine (1 mM) for the same time period since this dose has been previously shown to be efficacious in activation of mu-3 and-4 receptors. 1, 2, 9 In addition, it has been our contention that local concentrations
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Total RNA was extracted from 2 Â 10 6 MLPC after lysis in 600 ml RLT buffer (RLT) according to procedures outlined in the RNeasy mini kit (Qiagen, Germantown, MD, USA). RNA was eluted in 50 ml RNase-free H 2 O and a 750 ng aliquot was denatured at 95 1C and reverse transcribed at 40 1C for 1 h using random primers and Superscript III RNase H-Reverse Transcriptase (Invitrogen).
Gene array analysis of extracted human MLPC RNA Applied Biosystems Human Genome Survey Arrays were used to construct and differentially analyze by strict statistical criteria transcriptional/gene expression profiles of undifferentiated human MLPC in three independent experiments. The Applied Biosystems Human Genome Survey Array contains 31 700 60-mer oligonucleotide probes representing a set of 27 868 individual human genes and 41000 control probes. Sequences used for microarray probe design are from curated transcripts from the Celera Genomics Human Genome Database (www.celeradiscoverysystem.com), RefSeq transcripts that have been structurally curated from the LocusLink public database (http://www.ncbi.nlm.nih.gov/RefSeq/index. html), high-quality complementary DNA sequences from the Mammalian Gene Collection (http:// mgc.nci.nih.gov) and transcripts that were experimentally validated at Applied Biosystems Life Technologies (Carlsbad, CA, USA).
Pelleted MLPCs were resuspended in 600 ml of RLT buffer and homogenized by passing the lysate 20 times through a 1 ml pipette tip. The samples were then processed according to the manufacturer's detailed instructions. In the final step, the RNA was eluted with 50 ml of RNase-free water by centrifugation for 1 min at 10 000 r.p.m. The RNA was analyzed on a model 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) using a total RNA nanochip according to the manufacturer's protocol. Digoxigenin-UTP labeled complementary RNA was generated and linearly amplified from 1 mg of total RNA using Applied Biosystems Chemiluminescent RT-IVT Labeling Kit v2.0 and the manufacturer's protocol.
Array hybridization, chemiluminescence detection, image acquisition and analysis were performed using the Applied Biosystems Chemiluminescence Detection Kit and Applied Biosystems 1700 Chemiluminescent Microarray Analyzer according to protocols supplied by ABI. In all, 15 mg of labeled complementary RNA targets were hybridized to each chip at 55 1C for 19 h.
Statistical algorithm AB1700 Expression System software (Applied Biosystems Life Technologies) was used to extract assay signal, and assay signal-to-noise ratio values from the microarray images. Bad spots flagged by the software were removed from the analysis. For all genes scored, the fold change was calculated by dividing the average morphine-treated value by the average control assay value using the Spotfire DecisionSite software (TIBCO Spotfire, Somerville, MA, USA). If this number was o1, the reciprocal (negative) was listed. A change was deemed significant and reported in the lists containing genes X1.5-fold down (or up) based on the following criteria: the gene was scored, the fold change was X1.5-fold in the independent experiments, and the change in the values was above background values. Hence, genes with fold change values o1.5 and 4À1.5 were removed from the selected list of differentially expressed genes. Further gene filtering was accomplished through the application of a portfolio list containing a selection of 62 blood pressure (BP) regulation and hypertension-related genes by the use of the Spotfire DecisionSite software. Fold changes were combined and subjected to a one-way analysis of variance analysis using Sigmastat Software (Thompson's, Philadelphia, PA, USA).
Results
We sought to compare divergent cell types in this study to determine if there was a commonality in the expression of the genes of interest. Figures 1 and 2 , and Tables 1 and 2 show significantly altered expression profiles of hypertension-associated genes obtained from a literature search (see discussion) after exposure of the respective cells to morphine in vitro. All genes identified for examination came from a specific literature search. [10] [11] [12] [13] Interestingly, a similar pattern of change was observed for the majority of genes in both cell types,
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Fold Change Opiates and blood pressure M Banach et al that is, downregulation, indicating a selective inhibitory effect mediated by administered morphine. The only genes expressed in both cell types are b-adrenergic receptor kinase 2 (ADRBK2) and coding protein kinase WNK1 (PRKWNK1) (see Figure 3 , Table 3) ; however, only PRKWNK1 shows downregulation of its expression after morphine exposure. Interestingly, only two genes were observed to be upregulated after morphine treatment: ADRBK2 in stem cells and b3-adrenergic receptor in WBC. The functional downregulation of a1B-adrenergic receptor (ADRA1B) is consistent with the physiological role of the a-adrenergic receptor to promote pressure responses in vivo. Established classes of a-adrenergic blockers have been used as antihypertensive agents. 11 Concomitantly the upregulation of ADRBK2 is consistent with the role that the receptor kinase has in the functional desensitization of b-adrenergic receptors. The observed reciprocal changes in ADRA1B and ADRBK2 gene expression suggest that morphine acting through mu3/4 receptors is mediating coordinate physiological effects to regulate adrenergic pressor activity.
Finally, morphine administration to MLPC resulted in a significant downregulation of inducible NO synthase (iNOS) gene expression, the isoform associated with proinflammatory events. We have previously shown morphine-mediated reductions of iNOS gene expression in human endothelial cells. 14 These collected data suggest that morphine exerts a preemptive role against proinflammatory factors associated with hypertensive syndromes. Opiates and blood pressure M Banach et al
Discussion
The aim of this study was to examine morphinemediated changes in gene expression profiles of hypertension-associated candidate proteins using two independent cell models: preparations of human WBC and human MLPC. Morphine administration to primary cultures of human WBC and MLPC altered the expression profile of 16 candidate hypertension-associated genes. The majority of relevant genes was observed to be downregulated, suggesting ongoing homeostatic regulation by endogenous morphine coupled to NO production and release. Only two genes were observed to be significantly upregulated after morphine treatment: ADRBK2 in stem cells and b3-adrenergic receptor in WBC. A majority of the genes whose expression are altered by morphine treatment are secreted or act within the brain and central nervous system, while others are associated with the kidneys or vasculature. [1] [2] [3] In sum, these data suggest, but are not limited to a predominantly antihypertensive role for endogenous morphine/NO signaling events.
Endogenous morphine has been recently shown to be responsible for activating a mu3/mu4 receptor/ NO-coupled regulatory pathway that drives basic cellular autocrine or paracrine processes. Opioid-dependent modulation of gene expression was earlier observed in brain, spinal cord tissue and neuronal cell culture models. 15 Chronic exposure to morphine altered the expression pattern of such components of carbon monoxide/NO-cyclic guanosine monophosphate signaling cascade as haem oxygenases, NO synthase, soluble guanylate cyclase and cyclic guanosine monophosphate-dependent protein kinase. 15 Morphine was also shown to considerably reduce mean arterial pressure and heart rate in spontaneously hypertensive rats. 16 Altered expression of adrenergic receptor-associated genes In stem cells, the expression of ADRA1B was decreased, an effect not observed in WBC. Functional studies indicate that ADRA1B mediates contractile function in vessel beds and is critical in mediating sympathetic transmission at the neuroeffector junction and acute vascular responses to postural redistribution of blood volume. 17, 18 The functional downregulation of ADRA1B is consistent with the physiological role of the a-adrenergic receptor to promote pressure responses in vivo.
A morphine-mediated reduction in expression of b-adrenergic receptor kinase 1 (ADRBK1) was also observed in WBC. Previous work has shown that expression of ADRBK1 in lymphocytes (which correlated well with its vascular expression) and enzyme activity were enhanced in patients with hypertension. 19 Increased lymphocyte expression of ADRBK1 is negatively associated with b-adrenergic receptor-mediated adenylate cyclase activity, which suggests that increased expression of ADRBK1 may underlie the reduced b-adrenergic responsiveness. 20 Thus, the decrease in ADRBK1 expression in WBC after morphine treatment may be in agreement with its antihypertensive role. 20 An opposite pattern of change in the expression of ADRBK2 was observed in WBC and MLPC. ADRBK2 specifically phosphorylates the agonist-occupied form of the b-adrenergic and related G proteincoupled receptors. 19 The upregulation of ADRBK2 in MLPC is consistent with the role that the receptor kinase has in the functional desensitization of b-adrenergic receptor activity. Increased adrenergic receptor phosphorylation is likely to produce significant receptor/G-protein uncoupling, resulting in functionally decreased cellular pressor effects. Finally, the morphine-mediated enhancement of b3-adrenergic receptor gene expression in WBC is consonant with its putative role in positive regulation of the endothelium of coronary microarteries, 21 NO-dependent vasorelaxation of human coronary microarteries, 22 NO-mediated inhibition of adrenergic stimulation 23 and relaxation through K þ channel activation in rat aorta. 24 Altered expression of hypertension-associated candidate genes affecting endothelial cells Morphine administration was observed to diminish endothelin 3 (ET-3) expressions in WBC. ET-3, abundant in the brain and intestine, is one of the endothelium-derived vasoactive peptides involved in a variety of biological functions. 25 Decreased expression of ET-3 may be linked with reduced production of ET-1, whose vasoconstrictor effect may contribute to BP elevation and hypertension. [25] [26] [27] Accordingly, the dramatic morphine-mediated 10-fold reduction in ET-3 expression seems to be highly beneficial in maintaining normal BP.
Altered expression of hypertension-associated candidate genes expressed in kidney Expression of coding PRKWNK1 was decreased in both WBC and MLPC after morphine administration. WNK1 is primarily expressed in the distal nephrons of the kidney at sites involved in the regulation of Na þ Cl-reabsorption, which leads to volume expansion-induced hypertension. 28, 29 Interestingly, preclinical studies indicate a decrease in PRKWNK1 expression in heterozygous knockout mice, resulting in diminished BP levels. 28, 30 Thus, morphine-mediated decreases in PRKWNK1 expression putatively confirm both the antihypertensive properties of endogenously expressed morphine and its functional linkage to WNK1 in the modulation of BP levels.
Presently, we observed a morphine-mediated decrease in SLC12A6 expression in WBC. SLC12A6 is a cation chloride cotransporter and regulates cell volume, transepithelial salt absorption, renal K þ secretion, myocardial K þ loss during ischaemia and neuronal Cl-concentration. 31 In addition, we observed a similar decrease in adducin-1 expression in WBC after morphine treatment. Adducin, a heterodimeric membrane-cytoskeleton-associated protein, has been linked with essential hypertension. An adducin-1 polymorphism has been linked to salt-sensitive hypertension and increased Na þ /K þ pump activity. 32 Adipocytederived leucine aminopeptidase is suggested to have a role in the regulation of BP through the inactivation of angiotensin II and/or the generation of bradykinin in the kidney. 33 Both inactivation of angiotensin II and generation of bradykinin are functionally linked to vasodilatation.
We also observed a significant reduction in epoxide hydrolase (EPHX2) expression after morphine treatment. EPHX2, which is abundantly expressed in the kidney and localized to smooth muscle layers of the arterial wall, seems to have an important role for eicosanoids (epoxyeicosatrienoic acids) in renal vascular homeostasis. 34 Preclinically, EPHX2 was shown to be the predominant gene upregulated in spontaneously hypertensive rats. 34 Accordingly, decreased expression of EPHX2 observed in this study is in concordance with the beneficial, antihypertensive effects of endogenous morphine.
Altered expression of hypertension-associated candidate genes involved in proinflammation We observed a significant morphine-mediated decrease in iNOS in WBC. iNOS is expressed in a variety of tissues, including myocytes, small vessel endothelium, kidney, vascular smooth muscle and immune cells. 35 A locus for essential hypertension has been found recently in the vicinity of the iNOS gene (NOS2A) at 17cen-q11.2. 36 Moreover, studies in stroke-prone spontaneously hypertensive rats have shown that iNOS may have a pathophysiological role in early BP elevation. 37 We also observed a morphine-mediated decrease in type 1 tumour necrosis factor receptor shedding aminopeptidase regulator (ARTS-1) expression in WBC. ARTS-1 is functionally linked to antigen presentation to cytotoxic T lymphocytes and is believed to have a key role in the metabolism of several peptides that may be involved in BP regulation and the pathogenesis of essential hypertension. 38 Altered expression of hypertension-associated candidate genes in the adrenal gland Presently, we observed a morphine-mediated reduction in chromogranin A expression. Chromogranin A is an acidic-soluble protein present in adrenal medullary and sympathetic neuronal catecholamine storage vesicles. 39 Numerous studies have revealed that plasma chromogranin A levels are significantly enhanced in human essential hypertension. 40, 41 Preclinically, adrenal medullary chromaffin granule storage of chromogranin A was shown to be augmented in spontaneously hypertensive rats. 42 Concomitantly, we observed decreased expression of CYP11B2, the gene coding for human aldosterone synthase. CYP11B2 represents a cytochrome P450 enzyme, which catalyzes the terminal steps of aldosterone synthesis in the zona glomerulosa cells of the adrenal cortex. 43, 44 Genetic variance within CYP11B2 is associated with the development of salt-sensitive hypertension. 45 The decrease of CYP11B2 expression in MLPC after morphine stimulation is consistent with the role of this protein in hypertension development.
The study has some limitation, mainly connected to the fact that the functional consequences of morphine-mediated effects have not been tested yet.
Conclusions
Hypertension is a complex disease because many systems and factors contribute to the regulation of BP, such as the renin-angiotensin-aldosterone system, extracellular matrix and endothelins. Interactions between environmental factors regulating BP and genetic traits are necessary for the development of hypertension. The investigation of gene expression profiles that accompany hypertension may help identify potentially important causes of this disease and/or novel therapeutic targets. Studies have revealed that morphine might considerably reduce mean arterial pressure and heart rate. Endogenous morphine derived from defined cellular sources and circulating in plasma seems to provide an important caretaker role in promoting coordinated, on demand, vasomotor responsiveness, to diverse physiological stimuli. In this study, morphine treatment of WBC and stem cells altered the profile of expression of 16 candidate genes. A majority of the genes associated with BP regulation in this study were downregulated. These results may imply that endogenous morphine possesses antihypertensive properties. 46, 47 What is known about topic K Vascular endothelial cells functionally express a local autocrine-paracrine regulatory pathway driven by endogenously expressed, chemically authentic morphine.
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